

Living with Dravet syndrome



Dravet syndrome is a rare, devastating, and life-long developmental and epileptic encephalopathy that begins in infancy and is marked by frequent treatment-resistant seizures, significant cognitive, developmental and motor impairments that persist into adulthood, and an increased risk of Sudden Unexpected Death in Epilepsy (SUDEP).^{1,2,4,7,9}

Seizures associated with Dravet syndrome¹



Begin within the first year of life¹




Development is normal before seizure onset^{1,4,8}



Can sometimes be prolonged

lasting more than 5 minutes for tonic-clonic seizures (status epilepticus)³



Are drug-resistant¹³


Can be triggered by common daily occurrences⁴



Emotional stress or excitement⁸



Sunlight, flashing lights, or patterns⁸



Changes in body temperature^{4,8}


Who does Dravet syndrome impact?

Affecting one in 15,700 live births in the U.S. and approximately one in 20,000 to 40,000 live births in Europe, the impact of Dravet syndrome can be devastating in nature, as people often cannot care for themselves.^{3,4,10} Dravet syndrome is associated with lifelong deficits in cognition and behavior, as well as a constant need for monitoring due to the high frequency of seizures, motor impairments, and risk of death. Thus the disease doesn't just affect those with the condition, but also their families and caregivers.^{2,5,11}



66%

of caregivers experience depression due to the devastating nature of Dravet syndrome.¹¹



74%

of caregivers report concerns about the emotional impact on siblings of children with Dravet syndrome.¹¹

Dravet syndrome by the numbers:



Up to


20%

mortality rate with Dravet syndrome by age 20.^{3,12}



~85%

of people diagnosed with Dravet syndrome carry *SCN1A* gene mutations^{3,6}



Less than

10%

of people with Dravet syndrome are able to achieve freedom from their persistent seizures, even though more than 20 anti-seizure medications are currently on the market^{5,8}



How is Dravet syndrome treated?

Most people with Dravet syndrome are taking combinations of 3+ anti-seizure medications (ASMs).⁵

Despite treatment with multiple ASMs, many people continue to experience multiple seizures on a weekly or even daily basis that can persist throughout their lifetime.^{2,9,14} Existing treatment options may not be able to provide the amount of seizure control that people desire.⁹

The information provided is not intended to be used for diagnosis, treatment, or medical advice. It should not be used as a substitute for advice from a healthcare professional.

1. Dravet C. The Core Dravet Syndrome Phenotype. *Epilepsia*. 2011 Apr;52(Suppl 2):3-9.
2. Dravet C. Dravet syndrome history. *Dev Med Child Neurol*. 2011 Apr;53(Suppl 2):1-6.
3. National Organization for Rare Disorders. Dravet Syndrome. <https://rarediseases.org/rare-diseases/dravet-syndrome-spectrum>.
4. Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet Syndrome in the US Population. *Pediatrics*. 2015 Nov;136(5):e1310-1315.
5. Lagae L, Brambilla I, Mingorance A, et al. Quality of Life and Comorbidities Associated with Dravet Syndrome Severity: a Multinational Cohort Survey. *Dev Med Child Neurol*. 2018 Jan;60(1):63-72.
6. Wirrell EC, Laux L, Donner E, et al. Optimizing the Diagnosis and Management of Dravet Syndrome: Recommendations From a North American Consensus Panel. *Pediatr Neurol*. 2017 Mar;68:18-34.e3.
7. Cooper MS, McIntosh A, Crompton DE, et al. Mortality in Dravet syndrome. *Epilepsy Res*. 2016 Dec;128:43-47.
8. Granata T. Comprehensive Care of Children with Dravet Syndrome. *Epilepsia*. 2011 Apr;52 Suppl 2:90-94.
9. Aras LM, Isla J, Mingorance-Le Meur A. The European patient with Dravet Syndrome: Results from a Parent-reported Survey on Antiepileptic Drug use in the European Population with Dravet Syndrome. *Epilepsy Behav*. 2015 Mar;44:104-9.
10. UCB data on file. 2021.
11. Villas N, Meskis MA, Goodliffe S. Dravet syndrome: Characteristics, comorbidities, and caregiver concerns. *Epilepsy Behav*. 2017;74:81-86.
12. Cross JH, Galer BS, Gil-Nagel A, et al. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. *Seizure*. 2021;93:154-159.
13. Sullivan J, Wirrell EC. Dravet Syndrome as an Example of Precision Medicine in Epilepsy. *Epilepsy Currents*. June 2022.
14. Selvarajah A, Zulfiqar-Ali Q., Marques P., Rong M., Andrade D. M. A systematic review of adults with Dravet syndrome. *Seizure*. 2021 Feb; 40, 32.